Novartis statement regarding competition authority investigation into assertion of a patent
September 15, 2022 01:30 ET
|
Novartis Pharma AG
Company confident to clarify legitimacy of its position and fully cooperating with authorities Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition...
New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity
June 16, 2022 01:15 ET
|
Novartis Pharma AG
COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband...
Sandoz appoints new Board representative to global AMR Industry Alliance
May 27, 2022 03:00 ET
|
Novartis Pharma AG
Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life...
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
April 06, 2022 01:15 ET
|
Novartis Pharma AG
Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening...
Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
March 14, 2022 02:15 ET
|
Novartis Pharma AG
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading...
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
December 15, 2020 19:17 ET
|
Novartis International AG
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)Potential Q1 2021 sNDA approval...
European Medicines Agency (EMA) approves safety label update for Novartis Beovu®
September 14, 2020 06:15 ET
|
Novartis International AG
Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal vasculitis...
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
September 11, 2020 11:05 ET
|
Novartis International AG
Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the value of...
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
September 08, 2020 01:15 ET
|
Novartis International AG
Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for...
Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
September 07, 2020 01:15 ET
|
Novartis International AG
High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair...